Alder Biopharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ALDR)

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) was the target of unusually large options trading activity on Monday. Stock traders acquired 1,113 put options on the company. This is an increase of approximately 1,924% compared to the typical daily volume of 55 put options.

A number of research firms recently weighed in on ALDR. BidaskClub cut shares of Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday. BMO Capital Markets reissued a “buy” rating and set a $22.00 target price on shares of Alder Biopharmaceuticals in a research note on Wednesday, January 3rd. ValuEngine cut shares of Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Mizuho reaffirmed a “buy” rating and issued a $29.00 price objective (down previously from $32.00) on shares of Alder Biopharmaceuticals in a research note on Tuesday, January 9th. Finally, Canaccord Genuity set a $22.00 price objective on shares of Alder Biopharmaceuticals and gave the stock a “buy” rating in a research note on Friday, January 12th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. Alder Biopharmaceuticals has an average rating of “Hold” and an average target price of $27.93.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quantitative Systematic Strategies LLC acquired a new stake in Alder Biopharmaceuticals in the third quarter valued at approximately $132,000. SG Americas Securities LLC bought a new position in shares of Alder Biopharmaceuticals in the fourth quarter valued at approximately $132,000. Jane Street Group LLC bought a new position in shares of Alder Biopharmaceuticals in the third quarter valued at approximately $184,000. Paloma Partners Management Co bought a new position in shares of Alder Biopharmaceuticals in the fourth quarter valued at approximately $222,000. Finally, Teacher Retirement System of Texas bought a new position in shares of Alder Biopharmaceuticals in the fourth quarter valued at approximately $231,000. Hedge funds and other institutional investors own 95.34% of the company’s stock.

Alder Biopharmaceuticals (ALDR) traded up $0.70 during midday trading on Wednesday, reaching $14.55. 1,879,853 shares of the company’s stock were exchanged, compared to its average volume of 2,140,000. The firm has a market capitalization of $985.23, a PE ratio of -2.71 and a beta of 2.60. Alder Biopharmaceuticals has a 1 year low of $8.60 and a 1 year high of $24.65.

COPYRIGHT VIOLATION NOTICE: “Alder Biopharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ALDR)” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/02/21/stock-traders-buy-high-volume-of-put-options-on-alder-biopharmaceuticals-aldr-updated.html.

Alder Biopharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply